Ignite Creation Date:
2025-12-24 @ 7:02 PM
Ignite Modification Date:
2026-02-22 @ 5:21 PM
Study NCT ID:
NCT06307457
Status:
COMPLETED
Last Update Posted:
2025-06-29
First Post:
2024-03-05
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Study of HR+/HER2- Metastatic Breast Cancer Patients Treated With Palbociclib Together With an Aromatase Inhibitor From 2017 to 2023 in Denmark.
Sponsor:
Pfizer
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Breast Cancer | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | Metastatic Breast Cancer (mBC) | View |
| None | ICD10: C50 | View |
| None | Advanced Breast Cancer | View |
| None | HR+/HER2- | View |
| None | Hormone receptor positive / Human Epidermal growth factor Receptor 2 … | View |
| None | Endocrine sensitive | View |
| None | Endocrine resistant | View |
| None | de novo mBC | View |
| None | Denmark | View |
| None | Danish Breast Cancer Group (DBCG) | View |
| None | Palbociclib | View |
| None | Aromatase Inhibitor (AI) | View |
| None | Real-World Evidence (RWE) | View |
| None | Non-Interventional Study (NIS) | View |
| None | Age | View |
| None | Comorbidities | View |
| None | First-line Treatment | View |
| None | Charlson Comorbidity Index (CCI) | View |